Market capitalization | €1.69b |
P/E (TTM) P/E ratio | negative |
P/S ratio (TTM) P/S ratio | 5.73 |
Revenue growth (TTM) Revenue growth | -55.27% |
Revenue (TTM) Revenue | €295.45m |
EBIT (operating result TTM) EBIT | €-313.92m |
Free Cash Flow (TTM) Free Cash Flow | €-317.30m |
EPS (TTM) EPS | €-2.57 |
P/E forward | negative |
As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.
11 Analysts have issued a Galapagos forecast:
11 Analysts have issued a Galapagos forecast:
Mar '25 |
+/-
%
|
||
Revenue | 295 295 |
55%
55%
|
|
Gross Profit | 249 249 |
31%
31%
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -314 -314 |
93%
93%
|
Net Profit | -170 -170 |
151%
151%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Head office | Belgium |
CEO | Henry Gosebruch |
Employees | 704 |
Founded | 1999 |
Website | www.glpg.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.